RCUS PE Ratio & Valuation, Is RCUS Overvalued

Historical Valuation

Arcus Biosciences Inc (RCUS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 26.43 is considered Undervalued compared with the five-year average of -6.11. The fair price of Arcus Biosciences Inc (RCUS) is between 86.59 to 94.67 according to relative valuation method. Compared to the current price of 20.25 USD , Arcus Biosciences Inc By Undervalued By 76.61%.

Relative Value

Fair Zone

86.59-94.67

Current Price：20.25

76.61%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arcus Biosciences Inc (RCUS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arcus Biosciences Inc (RCUS) has a current Price-to-Book (P/B) ratio of 5.72. Compared to its 3-year average P/B ratio of 2.53, the current P/B ratio is approximately 125.73% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about 107.81% higher. Arcus Biosciences Inc (RCUS) has a Forward Free Cash Flow (FCF) yield of approximately -16.10%. Compared to its 3-year average FCF yield of -21.17%, the current FCF yield is approximately -23.93% lower. Relative to its 5-year average FCF yield of -7.81%, the current FCF yield is about 106.07% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RCUS competitors is 465.59, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS.N) exhibits a P/S ratio of 26.43, which is -94.32% above the industry average. Given its robust revenue growth of 26.92%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RCUS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RCUS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RCUS currently overvalued or undervalued?

What is Arcus Biosciences Inc (RCUS) fair value?

RCUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arcus Biosciences Inc (RCUS) is between 86.59 to 94.67 according to relative valuation method.

How does RCUS's valuation metrics compare to the industry average?

The average P/S ratio for RCUS's competitors is 465.59, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS) exhibits a P/S ratio of 26.43, which is -94.32% above the industry average. Given its robust revenue growth of 26.92%, this premium appears sustainable.

What is the current P/B ratio for Arcus Biosciences Inc (RCUS) as of Mar 25 2026?

As of Mar 25 2026, Arcus Biosciences Inc (RCUS) has a P/B ratio of 5.72. This indicates that the market values RCUS at 5.72 times its book value.

What is the current FCF Yield for Arcus Biosciences Inc (RCUS) as of Mar 25 2026?

As of Mar 25 2026, Arcus Biosciences Inc (RCUS) has a FCF Yield of -16.10%. This means that for every dollar of Arcus Biosciences Inc's market capitalization, the company generates -16.10 cents in free cash flow.

What is the current Forward P/E ratio for Arcus Biosciences Inc (RCUS) as of Mar 25 2026?

As of Mar 25 2026, Arcus Biosciences Inc (RCUS) has a Forward P/E ratio of -5.73. This means the market is willing to pay $-5.73 for every dollar of Arcus Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arcus Biosciences Inc (RCUS) as of Mar 25 2026?

As of Mar 25 2026, Arcus Biosciences Inc (RCUS) has a Forward P/S ratio of 26.43. This means the market is valuing RCUS at $26.43 for every dollar of expected revenue over the next 12 months.

RCUS Valuation